inPractice® - Genotype 2 Patients

Management of Hepatitis C Infection

Authors: Jordan J. Feld, MD, MPH; Hemant Shah, MD, MScCH HPTE (More Info)
Editor In Chief: Stefan Zeuzem, MD
Last Reviewed: 7/24/18 (What's New)

Summary

AASLD/IDSA guidelines recommend glecaprevir/pibrentasvir and sofosbuvir/velpatasvir as the preferred options for genotype 2 HCV–infected patients (Management Guidelines)^{[AASLD-IDSA HCV]}
- Sofosbuvir + daclatasvir regimens are alternative with duration depending on cirrhosis status
- Sofosbuvir/velpatasvir/voxilaprevir is the only regimen recommended for genotype 2 HCV–infected patients with sofosbuvir and NS5A inhibitor experience

Action required

Login now to access all of your entitled content
or
View additional options to gain access to this content

Keywords: Hepatitis C-Treatment